Cargando…

Clinical Safety of Expanded Hemodialysis Compared with Hemodialysis Using High-Flux Dialyzer during a Three-Year Cohort

Expanded hemodialysis (HD) equipped with a medium cut-off (MCO) membrane provides superior removal of larger middle molecules. However, there is still little research on the long-term benefits of expanded HD. Over a three-year period, this observational study evaluated the efficacy and safety profil...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Nam-Jun, Jeong, Seung-Hyun, Lee, Ka Young, Yu, Jin Young, Park, Samel, Lee, Eun Young, Gil, Hyo-Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025951/
https://www.ncbi.nlm.nih.gov/pubmed/35456352
http://dx.doi.org/10.3390/jcm11082261
_version_ 1784691003279540224
author Cho, Nam-Jun
Jeong, Seung-Hyun
Lee, Ka Young
Yu, Jin Young
Park, Samel
Lee, Eun Young
Gil, Hyo-Wook
author_facet Cho, Nam-Jun
Jeong, Seung-Hyun
Lee, Ka Young
Yu, Jin Young
Park, Samel
Lee, Eun Young
Gil, Hyo-Wook
author_sort Cho, Nam-Jun
collection PubMed
description Expanded hemodialysis (HD) equipped with a medium cut-off (MCO) membrane provides superior removal of larger middle molecules. However, there is still little research on the long-term benefits of expanded HD. Over a three-year period, this observational study evaluated the efficacy and safety profile of expanded HD for inflammatory cytokines, including IL-6. We conducted a prospective cohort study to investigate the inflammatory cytokine changes and a retrospective observational cohort study to investigate long-term clinical efficacy and safety over a three-year period. We categorized the patients according to dialyzer used: MCO and high-flux (HF) dialyzer. The inflammatory cytokines, including IFN-γ, IL-1β, IL-6, and TNF-α, were measured annually. The concentrations and changes of the four cytokines over time did not differ between the HF group (n = 15) and MCO group (n = 27). In both prospective and retrospective (HF group, n = 38; MCO group, n = 76) cohorts, there were no significant differences in either death, cardiovascular events, infections, or hospitalizations. Furthermore, the temporal changes in laboratory values, including serum albumin and erythropoietin prescriptions, did not differ significantly between the two groups in either the prospective or retrospective cohorts. In conclusion, clinical efficacy and safety outcomes, as well as inflammatory cytokines, did not differ with expanded HD compared with HF dialysis during a three-year treatment course, although the level of inflammatory cytokine was stable.
format Online
Article
Text
id pubmed-9025951
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90259512022-04-23 Clinical Safety of Expanded Hemodialysis Compared with Hemodialysis Using High-Flux Dialyzer during a Three-Year Cohort Cho, Nam-Jun Jeong, Seung-Hyun Lee, Ka Young Yu, Jin Young Park, Samel Lee, Eun Young Gil, Hyo-Wook J Clin Med Article Expanded hemodialysis (HD) equipped with a medium cut-off (MCO) membrane provides superior removal of larger middle molecules. However, there is still little research on the long-term benefits of expanded HD. Over a three-year period, this observational study evaluated the efficacy and safety profile of expanded HD for inflammatory cytokines, including IL-6. We conducted a prospective cohort study to investigate the inflammatory cytokine changes and a retrospective observational cohort study to investigate long-term clinical efficacy and safety over a three-year period. We categorized the patients according to dialyzer used: MCO and high-flux (HF) dialyzer. The inflammatory cytokines, including IFN-γ, IL-1β, IL-6, and TNF-α, were measured annually. The concentrations and changes of the four cytokines over time did not differ between the HF group (n = 15) and MCO group (n = 27). In both prospective and retrospective (HF group, n = 38; MCO group, n = 76) cohorts, there were no significant differences in either death, cardiovascular events, infections, or hospitalizations. Furthermore, the temporal changes in laboratory values, including serum albumin and erythropoietin prescriptions, did not differ significantly between the two groups in either the prospective or retrospective cohorts. In conclusion, clinical efficacy and safety outcomes, as well as inflammatory cytokines, did not differ with expanded HD compared with HF dialysis during a three-year treatment course, although the level of inflammatory cytokine was stable. MDPI 2022-04-18 /pmc/articles/PMC9025951/ /pubmed/35456352 http://dx.doi.org/10.3390/jcm11082261 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cho, Nam-Jun
Jeong, Seung-Hyun
Lee, Ka Young
Yu, Jin Young
Park, Samel
Lee, Eun Young
Gil, Hyo-Wook
Clinical Safety of Expanded Hemodialysis Compared with Hemodialysis Using High-Flux Dialyzer during a Three-Year Cohort
title Clinical Safety of Expanded Hemodialysis Compared with Hemodialysis Using High-Flux Dialyzer during a Three-Year Cohort
title_full Clinical Safety of Expanded Hemodialysis Compared with Hemodialysis Using High-Flux Dialyzer during a Three-Year Cohort
title_fullStr Clinical Safety of Expanded Hemodialysis Compared with Hemodialysis Using High-Flux Dialyzer during a Three-Year Cohort
title_full_unstemmed Clinical Safety of Expanded Hemodialysis Compared with Hemodialysis Using High-Flux Dialyzer during a Three-Year Cohort
title_short Clinical Safety of Expanded Hemodialysis Compared with Hemodialysis Using High-Flux Dialyzer during a Three-Year Cohort
title_sort clinical safety of expanded hemodialysis compared with hemodialysis using high-flux dialyzer during a three-year cohort
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025951/
https://www.ncbi.nlm.nih.gov/pubmed/35456352
http://dx.doi.org/10.3390/jcm11082261
work_keys_str_mv AT chonamjun clinicalsafetyofexpandedhemodialysiscomparedwithhemodialysisusinghighfluxdialyzerduringathreeyearcohort
AT jeongseunghyun clinicalsafetyofexpandedhemodialysiscomparedwithhemodialysisusinghighfluxdialyzerduringathreeyearcohort
AT leekayoung clinicalsafetyofexpandedhemodialysiscomparedwithhemodialysisusinghighfluxdialyzerduringathreeyearcohort
AT yujinyoung clinicalsafetyofexpandedhemodialysiscomparedwithhemodialysisusinghighfluxdialyzerduringathreeyearcohort
AT parksamel clinicalsafetyofexpandedhemodialysiscomparedwithhemodialysisusinghighfluxdialyzerduringathreeyearcohort
AT leeeunyoung clinicalsafetyofexpandedhemodialysiscomparedwithhemodialysisusinghighfluxdialyzerduringathreeyearcohort
AT gilhyowook clinicalsafetyofexpandedhemodialysiscomparedwithhemodialysisusinghighfluxdialyzerduringathreeyearcohort